Muriel Picard

Muriel Picard

Auto-generated profile, based on publicly available information

Muriel Picard

Service de Réanimation Polyvalente, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MSMarie Sabatier
Marie Sabatier
RBRudy Birsen
Rudy Birsen
LLLaura Lauture
Laura Lauture
SMSarah Mouche
Sarah Mouche
PAPaolo Angelino
Paolo Angelino
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely unknown in cancer. Here, multiomics analyses uncovered a coordinated activation of C/EBPα and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabolism in vivo and in patients with FLT3-mutant acute myeloid leukemia (AML). Mechanistically, C/EBPα regulated the fatty acid synthase (FASN)–stearoyl-CoA desaturase (SCD) axis to promote fatty acid (FA) biosynthesis and desaturation. We further demonstrated that FLT3 or C/EBPα inactivation decreased monounsaturated FA incorporation to membrane phospholipids through SCD downregulation. Consequently, SCD inhibition enhanced susceptibility to lipid redox stress that was exploited by combining FLT3 and glutathione peroxidase 4 inhibition to trigger lipid oxidative stress, enhancing ferroptotic death of FLT3-mutant AML cells. Altogether, our study reveals a C/EBPα function in lipid homeostasis and adaptation to redox stress, and a previously unreported vulnerability of FLT3-mutant AML to ferroptosis with promising therapeutic application. Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox stress downstream mutant-FLT3 signaling, which confers a vulnerability to ferroptosis upon FLT3 inhibition with therapeutic potential in AML. This article is highlighted in the In This Issue feature, p. 1501

1 August 2013 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MPMuriel Picard
Muriel Picard
SCSophie Cassaing
Sophie Cassaing
PLPhilippe Letocart
Philippe Letocart
XVXavier Verdeil
Xavier Verdeil
CPCaroline Protin
Caroline Protin
CRChristian Récher
Christian Récher

1 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ACAlban Canali
Alban Canali
IVInès Vergnolle
Inès Vergnolle
SBSarah Bertoli
Sarah Bertoli
LLLaetitia Largeaud
Laetitia Largeaud
MNMarie-Laure Nicolau
Marie-Laure Nicolau
FVFrancois Vergez
Francois Vergez
Purpose: Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) that carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating the clinical relevance of LSC abundance in AML. In 2018, the European LeukemiaNet published recommendations for the detection of measurable residual disease (Bulk MRD) and suggested the exploration of LSC MRD and the use of multiparametric displays. Experimental Design: We evaluated the performance of unsupervised clustering for the post-induction assessment of bulk and LSC MRD in 155 patients with AML who received intensive conventional chemotherapy treatment. Results: The median overall survival (OS) for Bulk+ MRD patients was 16.7 months and was not reached for negative patients (HR, 3.82; P < 0.0001). The median OS of LSC+ MRD patients was 25.0 months and not reached for negative patients (HR, 2.84; P = 0.001). Interestingly, 1-year (y) and 3-y OS were 60% and 39% in Bulk+, 91% and 52% in Bulk-LSC+ and 92% and 88% in Bulk-LSC−. Conclusions: In this study, we confirm the prognostic impact of post-induction multiparametric flow cytometry Bulk MRD in patients with AML. Focusing on LSCs, we identified a group of patients with negative Bulk MRD but positive LSC MRD (25.8% of our cohort) with an intermediate prognosis, demonstrating the interest of MRD analysis focusing on leukemic chemoresistant subpopulations.

1 April 2023
Verified
Other
Open access
ACAlban Canali
Alban Canali
IVInès Vergnolle
Inès Vergnolle
SBSarah Bertoli
Sarah Bertoli
LLLaetitia Largeaud
Laetitia Largeaud
MNMarie-Laure Nicolau
Marie-Laure Nicolau
FVFrancois Vergez
Francois Vergez
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients. Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients including the association of bulk and LSC MRD parameters. Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients including the association of bulk and LSC MRD parameters.

1 April 2023
Verified
Other
Open access
ACAlban Canali
Alban Canali
IVInès Vergnolle
Inès Vergnolle
SBSarah Bertoli
Sarah Bertoli
LLLaetitia Largeaud
Laetitia Largeaud
MNMarie-Laure Nicolau
Marie-Laure Nicolau
FVFrancois Vergez
Francois Vergez
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients. Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients including the association of bulk and LSC MRD parameters. Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients including the association of bulk and LSC MRD parameters.

16 September 2024
Verified
Other
Open access
MSMarie Sabatier
Marie Sabatier
RBRudy Birsen
Rudy Birsen
LLLaura Lauture
Laura Lauture
SMSarah Mouche
Sarah Mouche
PAPaolo Angelino
Paolo Angelino
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Table S5: GSEA results in FLT3-ITD PDX AML cells in vivo-treated with GILT or Veh.